AstraZeneca PLC (LON:AZN)

Market Cap	215.40B +22.8%
Revenue (ttm)	43.24B +13.5%
Net Income	6.99B +44.7%
EPS	4.48 +45.0%
Shares Out	1.55B
PE Ratio	31.02
Forward PE	18.31
Dividend	2.45 (1.76%)
Ex-Dividend Date	n/a

Volume	3,682,596
Average Volume	1,918,677
Open	13,952
Previous Close	13,888
Day's Range	13,748 - 14,314
52-Week Range	9,574 - 15,474
Beta	0.19
RSI	57.28
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD